Healthwell Acquisition Corp. I Acquires Starton Therapeutics to Create Public Continuous Delivery Platform

April 27, 2023

Starton Therapeutics and Healthwell Acquisition Corp. I entered into a definitive business combination agreement under which a newly formed Pubco subsidiary of Healthwell will acquire Starton and become a publicly traded company. The transaction is expected to close in the second half of 2023 and is designed to commercialize Starton’s proprietary continuous delivery technology for oncology therapeutics, including programs in multiple myeloma and chronic lymphocytic leukemia.

Buyers
Healthwell Acquisition Corp. I, HWEL Holdings Corp. (Pubco)
Targets
Starton Therapeutics, Inc.
Industry
Biotechnology
Location
New Jersey, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.